EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry - Wikidata - wikimedia - TriplyDB

EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry

EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry

http://www.wikidata.org/entity/Q35164306

about

FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Molecular pathology of lung cancer: key to personalized medicine.International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice.Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations Post-cancer Treatment with Condurango 30C Shows Amelioration of Benzo[a]pyrene-induced Lung Cancer in Rats Through the Molecular Pathway of Caspa- se-3-mediated Apoptosis Induction: -Anti-lung cancer potential of Condurango 30C in rats How close are we to customizing chemotherapy in early non-small cell lung cancer?Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer.Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients.Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles A time to test, a time to treat.Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma.LDA-SVM-based EGFR mutation model for NSCLC brain metastases: an observational study.Personalized targeted therapy for lung cancer Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.Parameters for individualizing systemic therapy in non-small cell lung cancer How and when to use genetic markers for nonsmall cell lung cancer.Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.Evaluation of Raman spectroscopy for diagnosing EGFR mutation status in lung adenocarcinoma.Fixation effect of SurePath preservative fluids using epidermal growth factor receptor mutation-specific antibodies for immunocytochemistry.Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study.[Advances on driver oncogenes of lung adenocarcinoma].High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas.Mutations in K-ras and epidermal growth factor receptor expression in Korean patients with stages III and IV colorectal cancer.Intrinsic cancer subtypes-next steps into personalized medicine

P2860

Q24296333-707EA9F5-3473-4A76-8956-44DA2F8FE24D Q26828860-5DFD7B96-C190-498F-930E-33317499ED69 Q27691299-6964A138-C181-42B3-8E00-EB41951DB563 Q28303718-F4573B33-852F-4C40-8BEF-0F1D0FA3843A Q33274011-8AC55819-2104-4C4E-8750-08B9C970816E Q33559365-635DC974-2938-4764-BD92-96F1BC317555 Q34159011-67E542F4-A48C-4598-89A3-0453C202CA5D Q34762165-5596E07C-E73E-405B-8F76-632F9EC809F6 Q34974942-EDDB46ED-7DF6-4CBA-B6DD-767E6D6F11C8 Q35036471-CCEC712A-1225-4739-8B97-F0744E554727 Q35093594-2A8A051E-040B-4642-95D1-93CE98E52D62 Q35146944-B3384409-E8CC-4E0F-A5C2-D48A7C32094A Q35549063-3614BE51-7B1D-4506-8A34-D2792B95212A Q35654769-729E3CD4-E646-4BDF-A857-11A1A1E83D5D Q35748487-23019B09-C674-473F-8DA2-8A84AC05C37B Q35889673-94BC74E2-E134-42D0-B186-F27E26766C62 Q36042345-87C9D05F-54E8-4FDC-85DF-36286C190DD9 Q36088709-79F5F959-1E74-42A5-9B01-697811022CF6 Q36152207-F39AD255-CE1A-4E94-87B8-24021B22F2E1 Q36321826-0DE6E982-E390-426E-8536-3DB63B28B685 Q36334470-CC34A4D7-9C98-4254-8509-410D87F92432 Q37051546-5B634576-6355-4F56-99CB-7114EBF7D5A5 Q37389605-9ED8AB50-586D-4DDB-8A3B-59CF5B03F8B7 Q37398845-3273EB82-BB42-4865-8B0C-30462C9448E4 Q37588365-130B09D6-FD6F-4766-A8A7-AA4B04DCC397 Q37667783-93BCED02-414B-4894-917C-59C58AB11570 Q37709234-973BA36A-E40B-4092-A7AF-5EF16C6B5474 Q38089481-748E04B1-A1A9-4709-945B-23C384B4AED2 Q39049295-3F72DBE8-C5E5-448B-8186-28FFE08AE4E4 Q39069260-9D74D21B-C4BF-4199-892D-F6E2F9A0FA2E Q42332672-663E06CE-CC19-4B2B-A20F-1E6E8F0CD250 Q47972274-3CA919D9-FCAC-41FC-8090-44984D58ED88 Q53257774-2AF33740-29DD-456C-9761-ACD9E8FEC919 Q54280116-305C8F5C-E70C-44BF-ABB0-01A7C9A4E45B Q54378950-18AF725F-DDA0-4284-8FAC-4DBDB5F061CD Q58053534-635A87D2-D62B-42EF-80D7-81FD6812AC05

P2860

EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry

http://www.wikidata.org/entity/Q35164306

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

EGFR mutation is a better pred ...... CISH, and immunohistochemistry

@ast

EGFR mutation is a better pred ...... CISH, and immunohistochemistry

@en

type

label

EGFR mutation is a better pred ...... CISH, and immunohistochemistry

@ast

EGFR mutation is a better pred ...... CISH, and immunohistochemistry

@en

prefLabel

EGFR mutation is a better pred ...... CISH, and immunohistochemistry

@ast

EGFR mutation is a better pred ...... CISH, and immunohistochemistry

@en

P1433

Q35164306-58221F5C-1F85-4971-81E3-AABCF9DD9D04

P1476

Q35164306-768AD6CC-80ED-4F1D-BF49-2CEFEB6F688E

P2093

Q35164306-088280AF-879F-46B2-9751-F230903A47A5

Q35164306-1AA7DBE0-9557-4C45-96B3-C8D5424807F9

Q35164306-28700980-7937-4467-A99B-A354042951F0

Q35164306-9C0CB0E2-AE52-4089-9AA7-DC94E7F9E66A

Q35164306-C64700E2-DD5E-4747-BC6F-891C103FC67D

Q35164306-CDA5EA59-D2FB-42E3-9022-5E73E986A2BA

Q35164306-D4516276-F46A-4091-B398-3D727E97F6C7

Q35164306-F680D9A7-A9D7-413E-AC98-315967D8C25D

P2860

Q35164306-0958D54D-13FF-418B-B0C3-4CC70575B29A

Q35164306-18E05223-AE3D-4834-A28A-A01135BF363C

Q35164306-1A804D8A-E88A-45C1-8D4A-956F26469490

Q35164306-1AA1BFD0-2C85-4498-9E04-5C8B93C8968C

Q35164306-2383BF42-0AD6-499B-9B67-F683AFB6E75E

Q35164306-28EA874F-AF18-4661-B13A-18DE45023C5B

Q35164306-30BA4A72-E152-4F9F-BF72-FB05D51A150E

Q35164306-31F58B8D-DE2D-48D2-847A-356960FB7D6A

Q35164306-337111CC-F902-495F-A0E7-16DCB3DB8712

Q35164306-358D3FA3-5C97-4F01-ABB6-D49AEA08A731

P304

Q35164306-2B205522-2192-434D-B046-01CD1089626F

P31

Q35164306-5D2A47AA-2EE8-4606-A7C7-0FCA7A72FB8B

P356

Q35164306-165C1BA7-A6F0-4B8B-9F3F-76465D6AF94C

P407

Q35164306-F1FC977D-FE39-4F75-A0ED-055E8C077B20

P433

Q35164306-32DD2510-E77D-4DC0-A205-09F523FE3E7D

P478

Q35164306-4126FBF9-849A-4018-AA64-6A262ADE04CA

P50

Q35164306-FB96B68C-FABF-45DA-9E2A-5968F61149C4

P577

Q35164306-08B03426-A250-4778-B2A2-F7101EC2A922

P698

Q35164306-454B90DF-DE25-42AA-AE08-1B087F03A634

P921

Q35164306-F67D73AE-7655-497A-9B68-1B63BFFBE9AF

P932

Q35164306-DB58AF60-413B-432D-9EAC-491CE4E51514

P356

AJCPST1CTHZS3PSZ

P1433

American Journal of Clinical Pathology

P1476

EGFR mutation is a better pred ...... CISH, and immunohistochemistry

@en

P2093

Beow Y Yeap

http://www.w3.org/2001/XMLSchema#string

Charles Lee

http://www.w3.org/2001/XMLSchema#string

David M Jackman

http://www.w3.org/2001/XMLSchema#string

Leigh-Anne Cioffredi

http://www.w3.org/2001/XMLSchema#string

Lynette M Sholl

http://www.w3.org/2001/XMLSchema#string

Neal I Lindeman

http://www.w3.org/2001/XMLSchema#string

Victoria Joshi

http://www.w3.org/2001/XMLSchema#string

Yun Xiao

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Somatic mutations affect key pathways in lung adenocarcinoma

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

922-934

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1309/AJCPST1CTHZS3PSZ

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

133

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20472851

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

P932

3156055

http://www.w3.org/2001/XMLSchema#string